Application and Clinical Effectiveness of Pelvic Reconstruction in Robot-assisted Radical Cystectomy-orthotopic Ileal Neobladder in the Male

Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04958343
Collaborator
First Affiliated Hospital, Sun Yat-Sen University (Other), Third Affiliated Hospital, Sun Yat-Sen University (Other), The Seventh Affiliated Hospital of Sun Yat-sen University (Other)
100
1
24
4.2

Study Details

Study Description

Brief Summary

To study the effect of pelvic reconstruction on early return of continence after robot-assisted radical cystectomy-orthotopic ileal neobladder in the male.

Condition or Disease Intervention/Treatment Phase
  • Procedure: pelvic reconstruction

Detailed Description

This study will enroll male patients with bladder cancer who will undergo robot-assisted radical cystectomy-orthotopic ileal neobladder. The patients will be distributed into two comparable groups according to whether received pelvic reconstruction or not. Patient demographics and pathologic, perioperative, functional, and oncologic outcomes will be compared between the two groups.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Application and Clinical Effectiveness of Pelvic Reconstruction in Robot-assisted Radical Cystectomy-orthotopic Ileal Neobladder in the Male
Anticipated Study Start Date :
Jul 2, 2021
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
reconstruction group

Patients will receive pelvic reconstruction following radical cystectomy during the operation.

Procedure: pelvic reconstruction
After radical cystectomy, the pelvic reconstruction including the ligation of dorsal vascular complex and posterior reconstruction will be performed on patients.

non-reconstruction group

Patients will not receive pelvic reconstruction following radical cystectomy during the operation.

Outcome Measures

Primary Outcome Measures

  1. day-time and night-time continence rate [6 months]

    Patients were considered continent when they required 0 or 1 safety pad during the day or at night.

Secondary Outcome Measures

  1. perioperative complication rate [3 months]

  2. operative time [24 hours]

  3. estimated blood loss [24 hours]

  4. overall survival [1 year]

  5. recurrence-free survival [1 year]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Male patients aged 18 or older.

  2. Patients those who are diagnosed with urothelial carcinoma.

  3. Patients those who are capable of receiving radical cystectomy with orthotopic ileal neobladder.

  4. Patients those who are able to cooperate and complete the follow-up.

  5. Patients those who volunteer to participate in this study and sign the informed consens.

Exclusion Criteria:
  1. Patients thsoe who are diagnosed distant metastasis before surgery.

  2. Patients those who are diagnosed with other malignancies.

  3. Patients those who had received pelvic radiotherapy or major pelvic operation.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sun Yat-sen Memorial Hospital, Sun Yat-sen University Guangzhou Guangdong China 510120

Sponsors and Collaborators

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • First Affiliated Hospital, Sun Yat-Sen University
  • Third Affiliated Hospital, Sun Yat-Sen University
  • The Seventh Affiliated Hospital of Sun Yat-sen University

Investigators

  • Principal Investigator: Jian Huang, MD, Sun Yat-sen Memorial Hospital,Sun Yat-sen University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
ClinicalTrials.gov Identifier:
NCT04958343
Other Study ID Numbers:
  • SysMU-RARC4
First Posted:
Jul 12, 2021
Last Update Posted:
Jul 12, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 12, 2021